A Study of Lisocabtagene Maraleucel (Liso-cel) for Transplant-Ineligible PCNSL
Phase 2
65
about 3.1 years
18+
30 sites in CA, CO, FL +10
Why this study is shown
What this study is about
Researchers are testing the safety and effectiveness of a treatment called lisocabtagene maraleucel (liso-cel) in adults with transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL). The trial will last about 1130 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Liso-cel
- 2.Take Calcium folinate
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
calcium folinate, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, methotrexate, procarbazine, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), temozolomide
infusion, oral (Oral Tablet), oral (Oral Capsule), injection, intravenous
Primary: Progression-free Survival (PFS)
Secondary: Complete Response Rate (CRR), Duration of Response (DoR), Event-free Survival (EFS), Health-related quality of life (HRQoL), Modified Progression-free Survival (mPFS), Overall Response Rate (ORR), Overall Survival (OS), PFS
Oncology